| Multiple Sclerosis |
1 |
0.67 |
| Immunization |
0 |
0.96 |
| COVID-19 |
0 |
0.8 |
| COVID-19 Vaccine |
0 |
0.69 |
| Vaccines |
0 |
0.6 |
| Biologic Therapy |
0 |
0.43 |
| Patient Safety |
0 |
0.39 |
| Pregnancy |
0 |
0.33 |
| Europe |
0 |
0.21 |
| T-Lymphocyte |
0 |
0.17 |
| Lymphocytes |
0 |
0.16 |
| Adverse Effects |
0 |
0.11 |
| Child |
0 |
0.11 |
| Disability |
0 |
0.11 |
| Glatiramer Acetate |
0 |
0.11 |
| Severe Acute Respiratory Syndrome |
0 |
0.11 |
| Steroids |
0 |
0.11 |
| Adenovirus |
0 |
0.05 |
| Adolescent Medicine |
0 |
0.05 |
| Clinical Research |
0 |
0.05 |
| Immune Reconstitution |
0 |
0.05 |
| Immunocompromise |
0 |
0.05 |
| Immunomodulator |
0 |
0.05 |
| Multiple Sclerosis Relapse |
0 |
0.05 |
| Multiple Sclerosis Treatment |
0 |
0.05 |
| Acute Respiratory Distress Syndrome |
0 |
0.04 |
| Obesity |
0 |
0.04 |